Racemates Less Safe. Rethink Chirality!
Synopsis Recently, an eye-opening commentary by Israel Agranat & Ilaria D’Acquarica, published in the European Journal of Pharmaceutical Sciences (2025), challenges a long-standing assumption in drug development: that single enantiomers are always the superior choice to racemic or diastereomeric mixtures in terms of efficacy and safety. Through historical analysis, case studies, and regulatory context, the …